Cargando…
The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
Recurrent glioblastomas (GBs) are highly aggressive tumors associated with a 6–8 mo survival rate. In this study, we evaluated the possible benefits of an immunotherapeutic strategy based on mature dendritic cells (DCs) loaded with autologous tumor-cell lysates in 15 patients affected by recurrent G...
Autores principales: | Pellegatta, Serena, Eoli, Marica, Frigerio, Simona, Antozzi, Carlo, Bruzzone, Maria Grazia, Cantini, Gabriele, Nava, Sara, Anghileri, Elena, Cuppini, Lucia, Cuccarini, Valeria, Ciusani, Emilio, Dossena, Marta, Pollo, Bianca, Mantegazza, Renato, Parati, Eugenio A., Finocchiaro, Gaetano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661164/ https://www.ncbi.nlm.nih.gov/pubmed/23802079 http://dx.doi.org/10.4161/onci.23401 |
Ejemplares similares
-
P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses
por: Pellegatta, S, et al.
Publicado: (2014) -
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide
por: Pellegatta, Serena, et al.
Publicado: (2018) -
Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment against Glioblastoma
por: Cuccarini, Valeria, et al.
Publicado: (2019) -
An Optimized Method for Manufacturing a Clinical Scale Dendritic Cell-Based Vaccine for the Treatment of Glioblastoma
por: Nava, Sara, et al.
Publicado: (2012) -
Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy
por: Eoli, Marica, et al.
Publicado: (2019)